Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 12;15(1):8586.
doi: 10.1038/s41598-025-93728-5.

ABO blood group system correlates with preoperative serum PSA level in patients with prostate cancer

Affiliations

ABO blood group system correlates with preoperative serum PSA level in patients with prostate cancer

Fangming Wang et al. Sci Rep. .

Abstract

We previously demonstrated that the non-O blood type is associated with a higher risk of aggressive prostate cancer (PCa) than the O blood type. However, the influence of the ABO blood phenotype on the exact risk stratification parameters, especially prostate-specific antigen (PSA), remains unknown. We retrospectively evaluated 426 patients with PCa underwent radical prostatectomy in our centers. We divided them into three groups based on PSA levels: PSA1 (< 10 ng/ml), PSA2 (10-20 ng/ml), and PSA3 (> 20 ng/ml), and compared the clinicopathological characteristics among the groups. The association of clinicopathological parameters with PSA was determined using logistic regression analyses. The percentages of patients with advanced pathological stage T (pT) and grade, lymph node (pN) involvement, A + AB type, perineural invasion (PNI), vessel carcinoma embolus (VCE), and positive surgical margin rate were significantly higher in the PSA3 group than in the PSA1 group (all p < 0.05). Univariate logistic regression analyses revealed that type A + AB, grade, pT, pN, PNI, and VCE were positively correlated with PSA levels when comparing PSA3 with PSA1. Multivariate analysis showed that the association between blood type A + AB and PSA levels remained significant (OR 1.810, 95% CI 1.061-3.086, for PSA2 vs. PSA1; OR 2.682, 95% CI 1.550-4.641, for PSA3 vs. PSA1) after adjusting for confounding factors. The A + AB blood type was independently associated with PSA levels in PCa patients, indicating that the A-allele might participate in PSA synthesis and PSA screening may be more efficient for A-allele carriers.

Keywords: ABO blood system; Prostate cancer; Prostate-specific antigen; Radical prostatectomy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The studies involving humans were reviewed and approved by the Ethical Committees of Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital and National Cancer Center. The studies were conducted in accordance with the local legislation and institutional requirements. Due to the retrospective nature of the study, the Ethical Committees of Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital waived the need of obtaining informed consent.

Figures

Fig. 1 A
Fig. 1 A
(A) Comparison of serum PSA levels among four different blood type groups. Data are expressed as median with interquartile range and presented in a violin plot (the dotted line), statistical significance is determined by the Kruskal–Wallis test, the figure was drawn using GraphPad Prism 8 software (GraphPad Software Inc., La Jolla, CA, USA). ns, not significant; *, p < 0.05; PSA, prostate-specific antigen. (B) Comparison of serum PSA levels between A + AB and B + O blood type groups. Data are expressed as median with interquartile range and presented in a violin plot (the dotted line), statistical significance is determined by the Mann–Whitney U test, the figures were drawn using GraphPad Prism 8 software (GraphPad Software Inc., La Jolla, CA, USA). *, p < 0.05; PSA, prostate-specific antigen.

References

    1. Bergengren, O. et al. 2022 update on prostate cancer epidemiology and risk factors-a systematic review. Eur. Urol.84, 191–206 (2023). - PMC - PubMed
    1. Culp, M. B. et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol.77, 38–52 (2020). - PubMed
    1. Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update part 1: Screening, diagnosis, and local treatment with curative intent. Eur. Urol.79, 243–262 (2021). - PubMed
    1. Costello, A. J. Considering the role of radical prostatectomy in 21st century prostate cancer care. Nat. Rev. Urol.17, 177–188 (2020). - PubMed
    1. Zhao, J. et al. Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility. Clin. Infect. Dis.73, 328–331 (2021). - PMC - PubMed

Substances